- Retroperitoneoscopic robot-assisted technique has favorable surgical and cancer control outcomes
- May be better for patients who have had previous abdominal surgery
- Variance in duration of operations between surgeons affects complications and may be reduced based on experience with UCLA surgical approach
- Knowing how pre-cancerous lesions develop paves the way for future personalized therapies to prevent lung cancer in at risk individuals
Roughly 50,000 Americans are diagnosed with kidney cancer per year. Most of these cancers are small tumors (small renal masses) that are often found during screening for other problems. Because of this, there are more surgeries scheduled to remove them. These surgeries can be difficult because of the location of the tumors if they are on the posterior side of the kidney, and because patients who have had previous abdominal surgery can have scar tissue that disrupts identification of normal anatomy.
Now researchers from UCLA’s Jonsson Comprehensive Cancer Center led by Dr. Jim Hu have shown that using a novel surgical technique called robot-assisted retroperitoneoscopic partial nephrectomy (RARPN), which provides an ideal approach in the setting of posterior renal masses or prior abdominal surgery. RARPN is a type of minimally invasive laparoscopic surgery in which the operation is done with precise robotic arms and magnified, high-definition 3-D cameras controlled by the surgeon.
Currently, many surgical centers use a technique called thermal ablation, which involves using a heat-producing probe, to eliminate small renal masses when they are difficult to reach. However, this technique is associated with an eight times higher need for CT scanning after surgery to keep watch on the tumors’ possible return, and greater frequency of CT scans resulting in more radiation exposure.
Another important finding of the 227-patient study was that there was significant variance between different surgeons in the amount of time the main blood supply to the kidney (renal artery) was blocked off during surgery. This time is called the warm ischemia time (WIT), which differed up to five minutes depending on the surgeon, even though all the surgeons in the study were fellowship-trained, high-volume surgeons at tertiary referral centers. However, greater surgeon experience was associated with shorter WIT. This is relevant, as longer WITs are associated with increased complications, such as acute kidney failure and long-term chronic kidney disease.
There were also significant differences in complications between surgeons, with a three-fold difference between the surgeon with the fewest compared to the most complications. However, major complications were relatively uncommon, with only three blood transfusions. Finally, less than one percent of patients experienced cancer recurrence during follow-up.
“These differences in WIT may be attributable to slight variations in surgical technique,” said Hu, who is also Director and Henry Singleton Chair in Robotic and Minimally Invasive Surgery. “But we showed center-specific variations in the RARPN approach and we present a video on surgical technique to highlight our approach.”
The RARPN study, published online in European Urology, was the largest multicenter study to date on this technique. The five-year study included patients who were 60 years-old on average. In addition to UCLA, participating centers included the University of Michigan and Swedish Medical Center in Seattle, WA.
About the Jonsson Comprehensive Cancer Center
UCLA's Jonsson Comprehensive Cancer Center has more than 240 researchers and clinicians engaged in disease research, prevention, detection, control, treatment and education. One of the nation's largest comprehensive cancer centers, the Jonsson center is dedicated to promoting research and translating basic science into leading-edge clinical studies. In July 2013, the Jonsson Cancer Center was named among the top 12 cancer centers nationwide by U.S. News & World Report, a ranking it has held for 14 consecutive years.
For more information on the Jonsson Cancer Center, visit our website at http://www.cancer.ucla.edu.